Jupiter Neurosciences (NASDAQ:JUNS) Issues Earnings Results

Jupiter Neurosciences (NASDAQ:JUNS) posted its earnings results on Friday. The company reported ($5.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($5.01), Zacks reports. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.40 million.

Jupiter Neurosciences Stock Down 12.7%

JUNS traded down $0.76 during trading on Friday, reaching $5.24. 105,488 shares of the company were exchanged, compared to its average volume of 318,208. Jupiter Neurosciences has a 12-month low of $4.56 and a 12-month high of $137.96. The company’s 50-day moving average is $12.93 and its two-hundred day moving average is $25.41. The company has a market cap of $4.03 million, a price-to-earnings ratio of -0.27 and a beta of 1.98.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on JUNS. Wall Street Zen upgraded Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Sunday. Weiss Ratings restated a “sell (e+)” rating on shares of Jupiter Neurosciences in a report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Trading of Jupiter Neurosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vestor Capital LLC increased its holdings in shares of Jupiter Neurosciences by 144,607.2% in the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock worth $365,000 after purchasing an additional 970,314 shares during the period. Geode Capital Management LLC increased its stake in Jupiter Neurosciences by 27.8% in the 4th quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after acquiring an additional 28,826 shares during the last quarter. Yorkville Advisors Global LP purchased a new stake in shares of Jupiter Neurosciences in the 4th quarter valued at about $135,000. Finally, Allen Capital Group LLC bought a new stake in shares of Jupiter Neurosciences during the 4th quarter valued at about $31,000.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.